First-dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: a report on ADVL0912 from the Children’s Oncology Group Phase 1/Pilot Consortium

PURPOSE: Characterize the pharmacokinetics of oral crizotinib in children with cancer. METHODS: Sixty-four children with solid tumors or anaplastic large-cell lymphoma (ALCL) enrolled on a phase 1/2 trial of the ALK, MET and ROS1 inhibitor, crizotinib, had pharmacokinetic sampling after the first do...

Descripción completa

Detalles Bibliográficos
Autores principales: Balis, Frank M., Thompson, Patrick A., Mosse, Yael P., Blaney, Susan M., Minard, Charles G., Weigel, Brenda J., Fox, Elizabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5225209/
https://www.ncbi.nlm.nih.gov/pubmed/28032129
http://dx.doi.org/10.1007/s00280-016-3220-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5225209/
https://www.ncbi.nlm.nih.gov/pubmed/28032129
http://dx.doi.org/10.1007/s00280-016-3220-6

Ejemplares similares